4th RNAi- Based Therapeutics Summit

Welcome to the 4rd Annual RNAi - Based Therapeutics Summit: Unleash the Potential of siRNA Therapies in Extrahepatic Tissues

Bringing together both technical and strategic expertise sharing case studies with actionable insights, the 4th RNAi-Based Therapeutics Summit returns to Boston to address the most pressing challenges preventing the widespread adoption of RNAi therapies and tackling targets beyond the liver.

With 20+ pioneering speakers from large pharma, innovative biotech, and KOLs of academia, join us to discuss novel delivery modalities, next-generation chemistries, clinical updates, scaling up. and more.

Speakers: Iris Grossman, Chief therapeutics officer, Eleven Therapeutics, Richard Welch, Vice President - Chemistry, Manufacturing and Controls, Sirnao, Debasis Patra, VP CMC, OliX US, Qi Tang, Postdoctoral Fellow, University of Massachusetts Medical School, Quintin Wills, CSO and Co-Founder, Ochre Bio Ltd., Nagy Habib, Head of R and D, MiNA Therapeutics, Brad Niles, CEO, ARIZ, Ali Shah, Co-Founder and Chief Executive Officer, Tallas Biotech, Ines de Santiago, Senior Principal Biologist, e-Therapeutics PLC, Anja Hog, Chief Development Officer, Heqet Therapeutics, Seungil Ro, Professor/President, University of Nevada, Reno School of Medicine/RosVivo Therapeutics, Dong-ki Lee, CEO, OliX Pharmaceuticals, Guangnong (Sunny) Zhang, Associate Director, Dicerna TRU of Novo Nordisk, Michael Khan, Chief Executive Officer, ARGONAUTE RNA Ltd., David Evans, Chief Scientific Officer, Sirnaomics, Alan Horsager, President and CEO, Duet Biotherapeutics, Samuel Wickline, Chief Scientific Officer, Altamira Therapeutics, June Park, CEO, siRNAgen Therapeutics, Sean Bedingfield, Advisor - Genetic Medicine, Eli Lilly and Co., Julia Alterman, Assistant Professor, University of Massachusetts Medical School, Yao Xin, Principal Investigator, Aro Biotherapeutics

Others Details

URL:
Brochure: https://go.evvnt.com/1424501-3?pid=6581